163 related articles for article (PubMed ID: 22783812)
1. Mn porphyrins as novel molecular magnetic resonance imaging contrast agents.
Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C
J Endourol; 2012 Nov; 26(11):1420-4. PubMed ID: 22783812
[TBL] [Abstract][Full Text] [Related]
2. Mn-porphyrins as novel molecular magnetic resonance imaging contrast agents.
Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C
J Endourol; 2011 Nov; ():1420-4. PubMed ID: 22050509
[TBL] [Abstract][Full Text] [Related]
3. Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+).
Gauter-Fleckenstein B; Reboucas JS; Fleckenstein K; Tovmasyan A; Owzar K; Jiang C; Batinic-Haberle I; Vujaskovic Z
Redox Biol; 2014; 2():400-10. PubMed ID: 24624330
[TBL] [Abstract][Full Text] [Related]
4. Superoxide dismutase mimic, MnTE-2-PyP(5+) ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum.
Archambeau JO; Tovmasyan A; Pearlstein RD; Crapo JD; Batinic-Haberle I
Redox Biol; 2013; 1(1):599-607. PubMed ID: 24363995
[TBL] [Abstract][Full Text] [Related]
5. Methoxy-derivatization of alkyl chains increases the in vivo efficacy of cationic Mn porphyrins. Synthesis, characterization, SOD-like activity, and SOD-deficient E. coli study of meta Mn(III) N-methoxyalkylpyridylporphyrins.
Tovmasyan AG; Rajic Z; Spasojevic I; Reboucas JS; Chen X; Salvemini D; Sheng H; Warner DS; Benov L; Batinic-Haberle I
Dalton Trans; 2011 Apr; 40(16):4111-21. PubMed ID: 21384047
[TBL] [Abstract][Full Text] [Related]
6. Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.
Keir ST; Dewhirst MW; Kirkpatrick JP; Bigner DD; Batinic-Haberle I
Anticancer Agents Med Chem; 2011 Feb; 11(2):202-12. PubMed ID: 21291403
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+.
Weitner T; Kos I; Sheng H; Tovmasyan A; Reboucas JS; Fan P; Warner DS; Vujaskovic Z; Batinic-Haberle I; Spasojevic I
Free Radic Biol Med; 2013 May; 58():73-80. PubMed ID: 23328731
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage.
Sheng H; Spasojevic I; Tse HM; Jung JY; Hong J; Zhang Z; Piganelli JD; Batinic-Haberle I; Warner DS
J Pharmacol Exp Ther; 2011 Sep; 338(3):906-16. PubMed ID: 21652782
[TBL] [Abstract][Full Text] [Related]
9. New class of potent catalysts of O2.-dismutation. Mn(III) ortho-methoxyethylpyridyl- and di-ortho-methoxyethylimidazolylporphyrins.
Batinić-Haberle I; Spasojević I; Stevens RD; Hambright P; Neta P; Okado-Matsumoto A; Fridovich I
Dalton Trans; 2004 Jun; (11):1696-702. PubMed ID: 15252564
[TBL] [Abstract][Full Text] [Related]
10. Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes.
Rebouças JS; Spasojević I; Batinić-Haberle I
J Pharm Biomed Anal; 2008 Nov; 48(3):1046-9. PubMed ID: 18804338
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor.
Rabbani ZN; Spasojevic I; Zhang X; Moeller BJ; Haberle S; Vasquez-Vivar J; Dewhirst MW; Vujaskovic Z; Batinic-Haberle I
Free Radic Biol Med; 2009 Oct; 47(7):992-1004. PubMed ID: 19591920
[TBL] [Abstract][Full Text] [Related]
12. Manganese-porphyrin reactions with lipids and lipoproteins.
Bloodsworth A; O'Donnell VB; Batinic-Haberle I; Chumley PH; Hurt JB; Day BJ; Crow JP; Freeman BA
Free Radic Biol Med; 2000 Apr; 28(7):1017-29. PubMed ID: 10832063
[TBL] [Abstract][Full Text] [Related]
13. Manganese porphyrin, MnTE-2-PyP, treatment protects the prostate from radiation-induced fibrosis (RIF) by activating the NRF2 signaling pathway and enhancing SOD2 and sirtuin activity.
Shrishrimal S; Chatterjee A; Kosmacek EA; Davis PJ; McDonald JT; Oberley-Deegan RE
Free Radic Biol Med; 2020 May; 152():255-270. PubMed ID: 32222469
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a metalloporphyrin antioxidant mimetic (MnTE-2-PyP) as a radiomitigator: prostate tumor and immune status.
Mehrotra S; Pecaut MJ; Freeman TL; Crapo JD; Rizvi A; Luo-Owen X; Slater JM; Gridley DS
Technol Cancer Res Treat; 2012 Oct; 11(5):447-57. PubMed ID: 22475066
[TBL] [Abstract][Full Text] [Related]
15. Redox modulation of oxidative stress by Mn porphyrin-based therapeutics: the effect of charge distribution.
Rebouças JS; Spasojević I; Tjahjono DH; Richaud A; Méndez F; Benov L; Batinić-Haberle I
Dalton Trans; 2008 Mar; (9):1233-42. PubMed ID: 18283384
[TBL] [Abstract][Full Text] [Related]
16. Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents.
Tovmasyan A; Carballal S; Ghazaryan R; Melikyan L; Weitner T; Maia CG; Reboucas JS; Radi R; Spasojevic I; Benov L; Batinic-Haberle I
Inorg Chem; 2014 Nov; 53(21):11467-83. PubMed ID: 25333724
[TBL] [Abstract][Full Text] [Related]
17. Lipophilicity is a critical parameter that dominates the efficacy of metalloporphyrins in blocking the development of morphine antinociceptive tolerance through peroxynitrite-mediated pathways.
Batinić-Haberle I; Ndengele MM; Cuzzocrea S; Rebouças JS; Spasojević I; Salvemini D
Free Radic Biol Med; 2009 Jan; 46(2):212-9. PubMed ID: 18983908
[TBL] [Abstract][Full Text] [Related]
18. Anticancer therapeutic potential of Mn porphyrin/ascorbate system.
Tovmasyan A; Sampaio RS; Boss MK; Bueno-Janice JC; Bader BH; Thomas M; Reboucas JS; Orr M; Chandler JD; Go YM; Jones DP; Venkatraman TN; Haberle S; Kyui N; Lascola CD; Dewhirst MW; Spasojevic I; Benov L; Batinic-Haberle I
Free Radic Biol Med; 2015 Dec; 89():1231-47. PubMed ID: 26496207
[TBL] [Abstract][Full Text] [Related]
19. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant.
Mackensen GB; Patel M; Sheng H; Calvi CL; Batinic-Haberle I; Day BJ; Liang LP; Fridovich I; Crapo JD; Pearlstein RD; Warner DS
J Neurosci; 2001 Jul; 21(13):4582-92. PubMed ID: 11425886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
